Bruker (BRKR) has a market capitalization of approximately $9.2B, trading at $60.40 on the NASDAQ. Market cap moves with the live share price.
Bruker's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Bruker runs a net profit margin of -0.3%, a gross margin of 45.6%, and an operating margin of 5.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Bruker reported revenue of
Bruker offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Bruker carries a debt-to-equity ratio of 0.68x and a current ratio of 1.55x, with a market beta of 1.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bruker (BRKR) the key facts are: market cap $9.2B, revenue
Get Bruker's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.